Postoperative treatment with pembrolizumab significantly improves the disease-free survival of patients with high-risk, clear cell renal cell carcinoma relative to placebo, show trial data.
People with stage II–IIIA non-small-cell lung cancer derive a significant disease-free survival benefit from adjuvant treatment with atezolizumab versus best supportive care, according to phase 3 trial results.
A de-escalated neoadjuvant regimen of pertuzumab and trastuzumab plus paclitaxel leads to “excellent” pathologic complete response rates and survival in people with hormone receptor-negative, HER2-positive early breast cancer, phase 2 study findings indicate.
Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.
